Detailed Information
Cited 37 time in 
Cited 39 time in 
Cited 39 time in
Metadata Downloads
Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose
- Authors
- Park, K.; Lee, J. -S.; Han, J. -Y.; Lee, K. H.; Kim, J. -H.; Cho, E. K.; Cho, J. Y.; Min, Y. J.; Kim, J. -S.; Kim, D. -W.
- Issue Date
- Apr-2016
- Publisher
- ELSEVIER SCIENCE INC
- Citation
- JOURNAL OF THORACIC ONCOLOGY, v.11, no.4, pp.S113 - S113
- Journal Title
- JOURNAL OF THORACIC ONCOLOGY
- Volume
- 11
- Number
- 4
- Start Page
- S113
- End Page
- S113
- ISSN
- 1556-0864
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Cho, Eun Kyung
- College of Medicine (Department of Medicine)